![]() |
|
|
Vol. 282, Issue 3, 1187-1197, 1997
Department of Anesthesia and Critical Care, The Pritzker School of
Medicine, The University of Chicago, Chicago, Illinois
The purposes of this study were to characterize the subjective,
psychomotor and physiological effects of buprenorphine in nondrug-abusing volunteers and to compare and contrast the effects of
equianalgesic doses of buprenorphine and morphine. Sixteen subjects
without histories of opiate dependence were injected in an upper
extremity vein with 0, 0.075, 0.15 or 0.3 mg/70 kg buprenorphine, or 10 mg/70 kg morphine, using a randomized, double-blind, cross-over design.
The 0.3-mg buprenorphine dose and 10-mg morphine dose are considered to
be equianalgesic and are doses commonly given for relief of
postoperative pain. Buprenorphine increased scores on the
Pentobarbital-Chlorpromazine-Alcohol Group scale and decreased scores
on the Benzedrine Group scale of the Addiction Research Center
Inventory, increased adjective checklist ratings of "nodding,"
"skin itchy," and "turning of stomach," and increased visual
analogue scale ratings of "dizzy," "nauseous" and "sleepy." Buprenorphine (0.3 mg) in general had subjective effects of greater magnitude than that of 10 mg morphine. Buprenorphine produced impairment on five measures of psychomotor performance in a
dose-related fashion. Ten mg morphine produced minimal psychomotor
impairment. Both buprenorphine and morphine induced miosis, but
buprenorphine (0.3 mg) had a larger and longer effect than that of 10 mg morphine. Buprenorphine, but not morphine, decreased respiration
rate. The results of our study demonstrate that 0.075 to 0.3 mg
buprenorphine had orderly, dose-related effects on subjective,
psychomotor and physiological variables. Further, a clinically relevant
dose of buprenorphine, 0.3 mg, produced a greater magnitude of
subjective and psychomotor-impairing effects than did an equianalgesic
dose of morphine.
This article has been cited by other articles:
![]() |
V. W. Rees, G. F. Wayne, and G. N. Connolly Puffing Style and Human Exposure Minimally Altered by Switching to a Carbon-Filtered Cigarette Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 2995 - 3003. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Comer, M. A. Sullivan, and E. A. Walker Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1320 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Comer, E. D. Collins, and M. W. Fischman Intravenous Buprenorphine Self-Administration by Detoxified Heroin Abusers J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 266 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Marsch, W. K. Bickel, G. J. Badger, J. P. Rathmell, M. D. B. Swedberg, B. Jonzon, and C. Norsten-Hoog Effects of Infusion Rate of Intravenously Administered Morphine on Physiological, Psychomotor, and Self-Reported Measures in Humans J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1056 - 1065. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Walker and J. P. Zacny Subjective, Psychomotor, and Physiological Effects of Cumulative Doses of Opioid µ Agonists in Healthy Volunteers J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1454 - 1464. [Abstract] [Full Text] |
||||